The estimated Net Worth of Scott B Capps is at least $3.48 Million dollars as of 15 December 2020. Mr. Capps owns over 10,000 units of Artivion Inc stock worth over $2,807,267 and over the last 17 years he sold CRY stock worth over $57,100. In addition, he makes $612,487 as Vice President - Clinical Research at Artivion Inc.
Scott has made over 9 trades of the Artivion Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CRY stock worth $99,700 on 15 December 2020.
The largest trade he's ever made was exercising 31,333 units of Artivion Inc stock on 13 February 2018 worth over $160,425. On average, Scott trades about 2,602 units every 93 days since 2008. As of 15 December 2020 he still owns at least 157,006 units of Artivion Inc stock.
You can see the complete history of Mr. Capps stock trades at the bottom of the page.
Scott B. Capps is Vice President - Clinical Research of the Company. He was appointed to the position of Vice President of Clinical Research in November 2007. Prior to this position, Mr. Capps served as Vice President, General Manager of CryoLife Europa, Ltd. in the U.K. from February 2005 to November 2007 and Director, European Clinical Affairs from April 2003 to January 2005. Mr. Capps joined CryoLife in 1995 as Project Engineer for the allograft heart valve program and was promoted to Director, Clinical Research in 1999. Mr. Capps is responsible for overseeing and implementing clinical trials to achieve FDA and International approval of CryoLife’s medical products in cardiac, vascular, and orthopaedic clinical areas. Before joining CryoLife, Mr. Capps was a Research Assistant in the Department of Bioengineering at Clemson University working to develop a computerized database and radiographic image analysis system for total knee replacement. Mr. Capps received his Bachelor of Industrial Engineering from the Georgia Institute of Technology and his M.S. in Bioengineering from Clemson University.
As the Vice President - Clinical Research of Artivion Inc, the total compensation of Scott Capps at Artivion Inc is $612,487. There are 6 executives at Artivion Inc getting paid more, with James Mackin having the highest compensation of $6,453,540.
Scott Capps is 53, he's been the Vice President - Clinical Research of Artivion Inc since 2007. There are 15 older and 6 younger executives at Artivion Inc. The oldest executive at Artivion Inc is Ronald McCall, 83, who is the Presiding Independent Director.
Scott's mailing address filed with the SEC is CRYOLIFE, INC., 1655 ROBERTS BLVD, NW, KENNESAW, GA, 30144.
Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman, and James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.
Artivion Inc executives and other stock owners filed with the SEC include: